Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1198-1209

  Qiu, Ying ^a,b   Morii, Eiichi ^b   Tomita, Yasuhiko ^d   Zhang, Binglin ^b   Matsumura, Akihide ^c   Kitaichi, Masanori ^d   Okumura, Meinoshin ^b   Aozasa, Katsuyuki ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BESTATIN; CISPLATIN; FLUOROURACIL DERIVATIVE; LUCIFERASE; MESSENGER RNA; MITOMYCIN; PICIBANIL; PRE B CELL LEUKEMIA TRANSCRIPTION FACTOR 2; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PBX1; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN; VINDESINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA FLANKING REGION; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA METASTASIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN DNA BINDING; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATASES; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 67449089655     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01156.x     Document Type: Article

References (31)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993; 54: 594-606.
2. Gridelli C, Rossi A, Galetta D et al. Italian clinical research in non-small-cell lung cancer. Ann Oncol 2005; 16: 110-5.
3. Pirozynski M. 100 years of lung cancer. Respir Med 2006; 100: 2073-84.
4. Yamamoto S, Tomita Y, Hoshida Y et al. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma. Ann Surg Oncol 2004; 11: 697-704.
5. Asai T, Tomita Y, Nakatsuka S et al. VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 2002; 93: 296-304.
6. Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem 1998; 273: 3562-73.
7. Dai RM, Li CC. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin-proteasome degradation. Nat Cell Biol 2001; 3: 740-4.
8. Yamamoto S, Tomita Y, Nakamori S et al. Elevated expression of valosin-containing protein (p97) in hepatocellular carcinoma is correlated with increased incidence of tumor recurrence. J Clin Oncol 2003; 21: 447-52.
9. Yamamoto S, Tomita Y, Hoshida Y et al. Expression level of valosin-containing protein is strongly associated with progression and prognosis of gastric carcinoma. J Clin Oncol 2003; 21: 2537-44.
10. Yamamoto S, Tomita Y, Hoshida Y et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res 2004; 10: 651-7.
11. Yamamoto S, Tomita Y, Hoshida Y et al. Expression level of valosin-containing protein (VCP) as a prognostic marker for gingival squamous cell carcinoma. Ann Oncol 2004; 15: 1432-8.
12. Qiu Y, Tomita Y, Zhang B, Nakamichi I, Morii E, Aozasa K. Pre-B-cell leukemia transcription factor 1 regulates expression of valosin-containing protein, a gene involved in cancer growth. Am J Pathol 2007; 170: 152-9.
13. Kamps MP, Murre C, Sun XH, Baltimore D. A new homeobox gene contributes the DNA binding domain of the t (1; 19) translocation protein in pre-B ALL. Cell 1990; 60: 547-55.
14. Nourse J, Mellentin JD, Galili N et al. Chromosomal translocation t (1; 19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 1990; 60: 535-45.
15. Dedera DA, Waller EK, LeBrun DP et al. Chimeric homeobox gene E2A-PBX1 induces proliferation, apoptosis, and malignant lymphomas in transgenic mice. Cell 1993; 74: 833 -43.
16. Mertelsmann R. Application of basic science to hematopoiesis and treatment of disease. Ann Oncol 1992; 3: 269-72.
17. Monica K, Galili N, Nourse J, Saltman D, Cleary ML. PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol Cell Biol 1991; 11: 6149-57.
18. Kamps MP, Look AT, Baltimore D. The human t (1; 19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials. Genes Dev 1991; 5: 358-68.
19. Phelan ML, Rambaldi I, Featherstone MS. Cooperative interactions between Hox and Pbx proteins mediated by a conserved peptide motif. Mol Cell Biol 1995; 15: 3989-97.
20. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001; 18: 1059-68.
21. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumours (ed 6). New York, NY: Wiley-Liss 2002.
22. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
23. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-41.
24. Palomares MR, Sayre JW, Shekar KC, Lillington LM, Chlebowski RT. Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. Cancer 1996; 78: 2119-26.
25. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-31.
26. Slebos RJ, Kibbelaar RE, Dalesio O et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323: 561-5.
27. Suzuki K, Nagai K, Yoshida J et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999; 86: 1976-84.
28. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: A national cancer data base report. Cancer 1999; 86: 1867-76.
29. Shimizu K, Yoshida J, Nagai K et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 2005; 130: 160 -5.
30. Sakao Y, Miyamoto H, Yamazaki A et al. Prognostic significance of metastasis to the highest mediastinal lymph node in non-small cell lung cancer. Ann Thorac Surg 2006; 81: 292 -7.
31. Okada Y, Nagai R, Sato T et al. Homeodomain proteins and PBXs regulate the lineage-specific transcription of the platelet factor 4 gene. Blood 2003; 101: 4748 -56.